CUBT OTC
Curative Biotechnology, Inc.
1W: -16.3%
1M: +4.0%
3M: -22.6%
YTD: +25.1%
1Y: -27.4%
3Y: -48.4%
5Y: -94.5%
$0.93
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$92K
+5.4% ▲
Operating Income
-$2M
-26.3% ▼
Net Income
-$4M
+9.9% ▲
EPS (Diluted)
$-0.00
+54.5% ▲
EBITDA
-$2M
+6.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $5K | $7K | $8K | $98K | $92K |
| Gross Profit | -$5K | -$7K | -$8K | -$98K | -$92K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $0 | $779K | $2M | $270K | $14K |
| SG&A Expenses | $5M | $4M | $2M | $2M | $2M |
| Operating Expenses | $5M | $5M | $4M | $2M | $2M |
| Operating Income | -$5M | -$5M | -$4M | -$2M | -$2M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $35K | $177K | $918K | $1M | $1M |
| Income Before Tax | -$5M | -$5M | -$5M | -$4M | -$4M |
| Tax Expense | $0 | $0 | $1M | $0 | $0 |
| Net Income | -$5M | -$5M | -$5M | -$4M | -$4M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.37 | $-0.04 | $-0.01 | $-0.01 | $-0.00 |
| EBITDA | -$5M | -$5M | -$4M | -$3M | -$2M |
| Shares Outstanding | 3M | 323M | 572M | 662M | 908M |